Loading
Vaccine Adverse Event Reporting System / COVID-19 Vaccines · Journal article
Human Vaccines & Immunotherapeutics · July 28, 2026
Early or partial results. Treat as a signal, not a conclusion.
This pharmacovigilance analysis identified potential vaccine-RA associations in VAERS data (1990–2026), with the strongest signals for Lyme disease (ROR 27.81), rubella (ROR 5.69), and anthrax (ROR 3.90) vaccines in specific populations, but weak signal for COVID-19 vaccine despite highest report volume. The study explicitly cannot establish causality and serves only to generate hypotheses for further investigation; RA-related vaccine adverse events remain extremely rare (0.03% of all reports).
Descriptive and disproportionality analysis of passive surveillance database. All VAERS reports (1990–2026); subset with RA-related adverse events (n=34,498 events, 5,006 subjects). Predominantly female (77.9%), age 18–65 years.. Intervention: Various vaccines (COVID-19, Lyme disease, rubella, anthrax, and others) as reported in VAERS.. Compared with: Reporting frequency baseline (disproportionality analysis comparing observed to expected reports).. n = 11,532,185. United States (VAERS is US-based surveillance system)..
Among 11,532,185 total VAERS reports, 34,498 RA-related adverse events (0.03%) involved 5,006 subjects Females comprised 77.9% of RA-related cases; age 18–65 predominated Serious outcomes occurred in 13.48% of RA-related adverse events
Among 11,532,185 total VAERS reports, 34,498 RA-related adverse events (0.03%) involved 5,006 subjects Serious outcomes occurred in 13.48% of RA-related adverse events
Clinicians should note that this signal detection study cannot confirm whether vaccines cause RA, only that certain vaccines (Lyme disease, rubella, anthrax) have higher reporting ratios in specific subgroups. The extremely low overall incidence (0.03%) and passive surveillance limitations mean clinical decision-making should await prospective validation and mechanistic studies before changing practice.
Pharmacovigilance signal detection study using passive surveillance data identifying potential vaccine-RA associations, but explicitly unable to establish causality or confirm safety; findings are hypothesis-generating only.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should note that this signal detection study cannot confirm whether vaccines cause RA, only that certain vaccines (Lyme disease, rubella, anthrax) have higher reporting ratios in specific subgroups. The extremely low overall incidence (0.03%) and passive surveillance limitations mean clinical decision-making should await prospective validation and mechanistic studies before changing practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Vaccination is a principal method of infectious disease prevention, but its association with rheumatoid arthritis (RA) remains controversial. This study assessed vaccine‑associated RA using the Vaccine Adverse Event Reporting System (VAERS). Data from 1990 to 2026 were extracted. Descriptive statistics, Weibull fitting, and disproportionality analysis using four methods, including the reporting odds ratio (ROR), along with subgroup analyses by age, sex, and pre‑/post‑COVID, were performed. Among 11,532,185 reports, 34,498 RA‑related adverse events (AEs) (0.03%) involved 5006 subjects. Females comprised 77.9% and 18-65 predominated. Serious outcomes occurred in 13.48%. Most AEs (47.49%) were musculoskeletal. 47.0% occurred within 7d (median 5.4), indicating early failure. The COVID‑19 vaccine had the most reports (n = 24,266) but a weak signal (ROR = 1.25); the Lyme disease vaccine (ROR = 27.81), the rubella vaccine (ROR = 5.69), and the anthrax vaccine (ROR = 3.90) exhibited the strongest signals. Subgroup signals: Lyme disease vaccine except 2021-2026; rubella vaccine only in females/≤17; anthrax vaccine in 18-64. RA‑related vaccine AEs are extremely rare, mainly musculoskeletal and within 1 week. High COVID‑19 volume did not align with its weak signal, while strong signals for the Lyme disease, rubella, and anthrax vaccines reflected specific populations. No strong disproportionality signal was found. However, VAERS is passive, cannot establish causality or confirm safety.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.